From the above, the activation of CDH13 expression by saRNA promotes cell apoptosis by inhibiting the NF-κB signaling pathway to overcome to BCR-ABL1-independent resistance to imatinib in patients with CML. This evidence concerns the gene CDH13 and chronic myelogenous leukemia, BCR-ABL1 positive.